The complexity of the treatment landscape for advanced NSCLC was further complicated by the advent of next-generation TKIs and immune checkpoint inhibitors and stratification of therapies by PD-L1 status.5,6 In addition, new but rare sequence variations, such as RET rearrangement, the BRAF V600E variant, MET exon 14 skipping, KRAS G12C variant, and NTRK1/2/3 gene fusion, were found, and targeted therapy for these variants was approved by the Korean Food and Drug Administration (KFDA). The gene discussed is BRAF; the disease is non-small cell lung carcinoma.